Ligand inks deal to acquire Taurus and xCella Biosciences
Ligand Pharmaceuticals Inc. (LGND) reported that it has inked a deal to acquire two companies, xCella Biosciences Inc. and Taurus Biosciences. Both these companies are privately held and are expected to boost Ligand’s OmniAb® technology platform. The company also plans to invest in a new company led by the founder of Taurus Biosciences.
Under the terms of the deals, Ligand will pay $7 million in cash to xCella for the acquisition. xCella will also be entitled to potential earnouts. Taurus Biosciences will be paid